Memantine Market - Size, Share, Outlook, and Opportunity Analysis 2018 – 2026 Memantine is a non-acetyl cholinesterase inhibitor drug that aids in treatment of Alzheimer's disease. The drug received European marketing approval in 2002 and the U.S. Food and Drug Administration (U.S FDA) approval in 2003. The generic versions of the drugs are available since 2015. Memantine aids in treatment of moderate to severe dementia associated with Alzheimer's disease. However the drug may show a severe skin reaction called Stevens-Johnson syndrome (associated with painful blisters on the skin) after prolonged use. Request Sample Copy of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2255 Memantine Market– Drivers Increasing number of pipeline studies for use of memantine are expected to boost growth of the memantine market. For instance, in September 2016, Lille University Hospital started phase I clinical study for assessing the effects of memantine on cognitive behavior of patients associated with Alzheimer’s disease. The study is estimated to be completed by February 2019. Furthermore, Suven Life Sciences Limited is undergoing phase II clinical study for the comparative study on safety and efficacy of SUVN-502 along with memantine HCl and donezepil HCl for treating moderate Alzheimer’s disease. The study was started in September 2015 and is expected to be completed in May 2019. Memantine Market– Restraint Increasing number of expired patents of drugs is a major factor hindering growth of the global memantine market. For instance, according Merz Pharmaceuticals, a Germany-based company, in October 2018, overall licensing income during patented period for memantine decreased due to expiration of patent protection in a majority of markets. For instance, according to Merz Pharmaceuticals, the U.S. licensing income for memantine declined to US$ 138.07 million in 2017-18 compared to US$ 183.34 million in year 2016. Report includes chapters which deeply display the following deliverable about industry : • Memantine Market Research Objective and Assumption • Memantine Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM) • Memantine Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Memantine Market, By Regions • Memantine Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Memantine Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Memantine Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Memantine Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion Memantine Market– Regional Analysis On the basis of region, the global memantine market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold dominant position in the global memantine market, owing to increasing number of generic versions of memantine in the U.S. market. For instance, in February 2018, Lupin Limited announced the launch of its Memantine Hydrochloride ExtendedRelease Capsules in the U.S. market. The capsules are available in 7mg, 14mg, 21mg, and 28mg, for which company has received an approval from the U.S. FDA. These are indicated for the treatment of moderate to severe dementia of the Alzheimer’s disease. Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2255 Furthermore, Asia Pacific is expected to witness significant growth in the global memantine market, owing to increasing focus of key players in manufacturing memantine tablets. For instance, in October 2018, Dr. Reddy’s Laboratories launched memantine hydrochloride tablets in the Indian market. They are available in 5mg and 10mg, equivalent to generic version of Namenda tablets, which were already available in the U.S. market in July 2015. Memantine Market– Competitive Analysis Key players operating in the global memantine market include, Merz Pharmaceuticals, Lupin Limited, Allergan plc. Novartis AG, Daiichi Sankyo Company, Limited, Ono Pharmaceutical Co Ltd., Eisai Co., Ltd., H. Lundbeck A/S, Dr. Reddy’s Laboratories, and Johnson & Johnson Services, Inc. About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]
Memantine is a non-acetyl cholinesterase inhibitor drug that aids in treatment of Alzheimer's disease.
© Copyright 2024 Paperzz